No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABCL AbCellera Biologics
- 3.910
- -0.010-0.26%
Close Apr 18 16:00 ET
- 3.960
- +0.050+1.28%
Post 18:54 ET
1.14BMarket Cap-7666P/E (TTM)
3.970High3.840Low765.65KVolume3.950Open3.920Pre Close3.00MTurnover0.40%Turnover RatioLossP/E (Static)292.78MShares8.05052wk High0.99P/B749.77MFloat Cap3.84052wk Low--Dividend TTM191.76MShs Float71.910Historical High--Div YieldTTM3.32%Amplitude3.840Historical Low3.917Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain fo
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
AbCellera (NASDAQ:ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024,
Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
Over the last year, a good number of insiders have significantly increased their holdings in AbCellera Biologics Inc. (NASDAQ:ABCL). This is encouraging because it indicates that insiders are more opt
Comments
Insiders at AbCellera Biologics Inc. are increasing their holdings, indicating optimism about the company's prospects. Their willingness to buy shares at a higher price suggests they see value in the company.
Insider Stock Buying Reaches US$1.61m On AbCellera BiologicsKeyBanc views current lower subsector stock prices as a valuable opportunity for long-term investors. The bank advises a detailed, company-specific approach to investment, highlighting Abcellera ($6), Absci ($3), and Schrodinger ($38) for their proven track records, AI focus, and recurring revenue growth, respectively.
1
Inside buy
$AbCellera Biologics(ABCL.US$ Director Montalbano John S. purchased 30,000 shares of Common Stocks on Nov 6, 8, 2023 at an average price of $4.58 for a total value of $137.4K.
1
7
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg